Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
F-18 FEDAA1106 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Arm 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| F-18 FEDAA1106 (BAY85-8101) | DRUG | MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer \< 5 µg, PET |
Inclusion Criteria: Healthy volunteers for brain imaging: * males or females, age 20 - 55 years * assessment of the brain MRI as "normal (age-appropriate)" * absence of any sign of CNS disease, no co-medi cation Patients for brain imaging * males or females, age 20 - 55 years * patients with previ...
F-18 FEDAA1106 is an investigational small molecule being developed for use in positron-emission tomography (PET), a type of medical imaging. It is being studied in the context of neurological conditions, specifically multiple sclerosis and Alzheimer's disease, where it may help visualize biological processes in the brain.
F-18 FEDAA1106 is being developed by Bayer AG, a German pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY.
F-18 FEDAA1106 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and potential uses.
F-18 FEDAA1106 has been studied in two completed Phase 1 clinical trials. One trial (NCT01031199) evaluated the PET tracer in patients with multiple sclerosis compared to healthy volunteers. The other trial (NCT01035164) evaluated it in probable Alzheimer's disease patients versus healthy volunteers and assessed radiation dosimetry in healthy volunteers.
Yes, F-18 FEDAA1106 is also known as ZK 6032924. Both names refer to the same investigational PET tracer being developed by Bayer AG for imaging in neurological conditions such as multiple sclerosis and Alzheimer's disease.